source
- Jury awards Nektar $90 million in damages after lawsuit over broken rezpeg partnership with Eli LillyA jury in a US court has ordered Eli Lilly to pay Nektar Therapeutics $90 million after finding the pharma giant breached their collaboration on the experimental autoimmune drug rezpeg. Nektar and…
- FDA approves Eli Lilly’s weekly insulin Onswik for U.S. patients, expanding competition with NovoThe U.S. Food and Drug Administration has cleared Eli Lilly’s weekly insulin product, Onswik, for use in American patients. This marks the drug’s fourth global approval after earlier clearances in…